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Type 2 diabetes mellitus is a complex disorder associated with multiple genetic, epigenetic, developmental, and
environmental factors. Animal models of type 2 diabetes differ based on diet, drug treatment, and gene knockouts,
and yet all display the clinical hallmarks of hyperglycemia and insulin resistance in peripheral tissue. The recent
advances in gene-expression microarray technologies present an unprecedented opportunity to study type 2 diabetes
mellitus at a genome-wide scale and across different models. To date, a key challenge has been to identify the
biological processes or signaling pathways that play significant roles in the disorder. Here, using a network-based
analysis methodology, we identified two sets of genes, associated with insulin signaling and a network of nuclear
receptors, which are recurrent in a statistically significant number of diabetes and insulin resistance models and
transcriptionally altered across diverse tissue types. We additionally identified a network of protein–protein
interactions between members from the two gene sets that may facilitate signaling between them. Taken together, the
results illustrate the benefits of integrating high-throughput microarray studies, together with protein–protein
interaction networks, in elucidating the underlying biological processes associated with a complex disorder.
Citation: Liu M, Liberzon A, Kong SW, Lai WR, Park PJ, et al. (2007) Network-based analysis of affected biological processes in type 2 diabetes models. PLoS Genet 3(6): e96.
doi:10.1371/journal.pgen.0030096
Introduction
Type 2 diabetes mellitus (DM2) is a metabolic disorder
characterized by abnormal hepatic glucose output, insulin
resistance, and impaired insulin production [1,2]. DM2 has
reached epidemic proportions and currently affects about
170 million people worldwide, with the figure projected to
more than double by 2030 [3]. The driving force behind the
high prevalence of diabetes is the rise of obesity in the
population [4]. In the United States alone, a startling 32% of
the population is classified as obese [5]. The long-term
complications of DM2 include atherosclerotic vascular dis-
ease, heart disease, retinopathy, kidney failure, and amputa-
tion [3].
DM2 is currently believed to be a multifactorial, complex
disease [6–8]. While patients may all exhibit the aforemen-
tioned classical set of symptoms, individual cases can vary
significantly in their internal cause–effect physiological
mechanisms. The same diversity in the biology underlying
the disorder also appears among the different animal models.
Although they may all exhibit hyperglycemia and insulin
resistance to certain degrees, the organisms differ with
respects to diet, drug treatment, and gene knockouts.
The framework described in this paper is aimed to address
two key questions: (1) Can biological processes be identified
that are consistently deregulated in different models of
insulin resistance and diabetes and that may be manifested in
a tissue-dependent or independent manner? (2) On a higher
level, can tissue or condition-specific interaction networks be
identified that more precisely characterize different insulin-
resistance models and suggest causal mechanisms?
By identifying key biological processes and genes involved
in the pathogenesis of diabetes, novel drug targets for the
disease and related metabolic disorders such as obesity and
metabolic syndrome may be determined.
We began the investigation by focusing on insulin-signaling
genes, a natural and well-established candidate for finding a
signature set of genes associated with insulin resistance or
diabetes [9]. In particular, by examining microarray data, we
attempted to detect a statistically significant, transcriptional
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alteration in a set of insulin-signaling genes in diabetic tissue
compared to normal. Surprisingly, using existing analytical
methods, we were unable to detect such alterations in
microarray data produced in several human studies. Using
sophisticated and remarkably sensitive techniques, previous
studies identified the oxidative phosphorylation pathway as
transcriptionally down-regulated in diabetic muscle tissue
compared to normal [10,11]. However, insulin-signaling gene
sets were not detected to be transcriptionally altered, using
state of the art analyses, more than expected by chance.
Since insulin signaling is a key biological process involved
in insulin resistance, our inability to detect its transcriptional
alteration in diabetes posed a scientific and methodological
challenge. We consequently analyzed a set of microarray
datasets, generated by the Diabetes Genome Anatomy Project
(DGAP) [12], from different experiments of insulin resistance
and diabetes in mouse models and human patients. A number
of these experiments directly perturbed critical components
of insulin signaling and hundreds of genes were observed
differentially expressed in the disease state. Using a well-
established and widely used methodology for detecting
significantly altered biological processes, we were again
unable to detect a significant change in insulin signaling in
these experiments.
The inability to detect insulin-signaling changes in both
studies can be explained by a number of technical and
biological hypotheses. First, perhaps the number of insulin-
signaling genes that were transcriptionally deregulated was
too few to be considered significant by statistical procedures.
Second, perhaps the assembled insulin-signaling gene set
used in our analysis did not accurately capture the transcrip-
tional alterations in insulin signaling. Alternatively, it is
plausible that the changes in a diabetic state were produced
by phosphorylation-mediated signaling that was not detected
by transcriptional profiling.
We decided to pursue the first hypothesis and adapted a
systems biology perspective. Rather than looking for signifi-
cant aberrations in expression of individual insulin-signaling
genes, we looked for significant aberrations in the collective
expression of a set of insulin-signaling genes whose protein
products form a connected protein–protein interaction
network. This was accomplished using a simple methodology
referred to as gene network enrichment analysis (GNEA).
Application of GNEA to the microarray datasets convinc-
ingly identified a set of insulin-signaling genes (denoted as IS-
HD) as significantly transcriptionally altered in insulin
resistance and the DM2 phenotype. Additionally, GNEA
identified another transcriptionally altered set of genes
containing many nuclear receptor and nuclear receptor
cofactors (denoted as NR-HD). The NR-HD set contained
such genes as peroxisome proliferative activated receptor, gamma,
coactivator 1 alpha (PPARGC1A, also known as PGC1A),
peroxisome proliferative activated receptor, gamma (PPARG), and
hepatocyte nuclear factor 4 alpha 1 (HNF4A), whose associations
with the DM2 phenotype were well established [10,13–17]. To
our knowledge, this was the first genome-wide study that
addressed the broad transcriptional role of a set of nuclear
receptors in different insulin resistance and DM2 models, on
the basis of integration of gene-expression data from diverse
models of the disorder. In particular, the results demon-
strated the consistent deregulation of a set of insulin-
signaling genes and a set of nuclear receptors in multiple
insulin-resistance models.
Methods
GNEA Overview
GNEA aims to identify biological processes that are
consistently deregulated across a broad set of microarray
experiments associated with different disease models in both
human and animal tissues. This differs from conventional
statistical methods that typically focus on finding biological
processes affected in a single microarray experiment. Similar
to gene-set enrichment analysis (GSEA) [18], the approach
allows for the inclusion of moderately expressed genes, which
may be missed by traditional tests for differential expression.
GNEA is motivated by the following model. The cell is
associated with a protein–protein interaction network, and
each protein is labeled as belonging to one or more gene sets
associated with biological processes or molecular function.
This labeling defines overlapping functional subnetworks of
related proteins. Such a model can be formalized as a
biological context network, and previous studies have shown
that the distribution of labels per protein follows a power law
distribution [19].
When the cell enters a perturbed state, some subset of the
interaction network becomes differentially affected. The
hypothesis is that certain functional subnetworks may show
significantly altered activity in the perturbed state compared
to normal. Such functional subnetworks may be identified
using statistical methods such as GNEA.
The basic framework for GNEA consists of five steps: (1)
Assemble a collection of gene sets associated with biological
processes or signaling pathways of interest (for example,
insulin signaling). (2) Assume an underlying model of cellular
processes using a global protein–protein interaction network,
imported from the literature. We associate each protein in
the interaction network with the relative change in mRNA
expression between an insulin resistant or diabetic state and
normal condition. Based on the interaction network and gene
expressions, we find a subnetwork (designated as the high-
scoring subnetwork [HSN]) that is highly transcriptionally
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Author Summary
Type 2 diabetes mellitus currently affects millions of people. It is
clinically characterized by insulin resistance in addition to an
impaired glucose response and associated with numerous compli-
cations including heart disease, stroke, neuropathy, and kidney
failure, among others. Accurate identification of the underlying
molecular mechanisms of the disease or its complications is an
important research problem that could lead to novel diagnostics
and therapy. The main challenge stems from the fact that insulin
resistance is a complex disorder and affects a multitude of biological
processes, metabolic networks, and signaling pathways. In this
report, the authors develop a network-based methodology that
appears to be more sensitive than previous approaches in detecting
deregulated molecular processes in a disease state. The method-
ology revealed that both insulin signaling and nuclear receptor
networks are consistently and differentially expressed in many
models of insulin resistance. The positive results suggest such
network-based diagnostic technologies hold promise as potentially
useful clinical and research tools in the future.
affected in the disease state. (3) Evaluate the hypothesis that
genes in a given gene set are observed in a higher proportion
(i.e., enriched) than expected by chance in the HSN and
repeat for each gene set in the assembly. Repeat (2) and (3) for
every insulin resistant or diabetic condition compared to
normal in the dataset. (4) Order the gene sets of interest
based on the number of different HSNs where they appear
enriched. (5) For each gene set, assign a p-value to the number
of conditions where it is enriched. The gene sets with a
significant p-value are taken as transcriptionally affected
across a broad set of diabetes-related models. Consistent with
the stated goal of GNEA, gene sets enriched in a few
conditions, while potentially interesting in their own right,
will not generally be assigned a significant p-value (Figure 1).
To assess the effectiveness of GNEA, we also compared its
performance against the conventional hypergeometric en-
richment test for differentially expressed genes (DEA) and
GSEA [18]. The basic outline for DEA is similar to GNEA
without the incorporation of protein–protein interaction
information. Complete details are given in Figure S1.
Assembling Gene Sets for Testing with GNEA
We collected and tested two groups of gene sets separately.
One group contained gene sets potentially associated with
DM2, based on composition of its members, and included IS-
HD, NR-HD, two manually curated retinol signaling and
metabolism sets, and three additional nuclear receptor gene
sets compiled from the nuclear receptor superfamily, labeled
nuclear receptors from the HUGO gene nomenclature
committee, and the union of the two. The selection of retinol
signaling and nuclear receptor gene sets was motivated by
previous studies, suggesting a possible connection between
retinol signaling, DM2, and related metabolic disorders, as
well as by the established roles between individual nuclear
receptors and metabolic processes. The IS-HD gene set was
taken directly from the Human Protein Reference Database
(HPRD) [20], a public compilation of protein–protein
interactions. The NR-HD gene set was manually compiled
and curated. The other group contained 346 gene sets from
gene ontology (GO) categories present in the DGAP
expression data that fell within a minimum and maximum
size threshold. See Text S2 for details.
Mapping Gene Expression to a Protein–Protein Interaction
Network
The gene-expression data were a compilation of diverse
gene-expression datasets of diabetes and insulin resistance
models derived from a collection of 361 oligonucleotide
Figure 1. Overview of GNEA
(1) A collection of gene sets associated with biological processes was assembled. (2) The relative mRNA expression of every gene in each insulin
resistance or diabetes condition was mapped to the associated protein in a global network of protein–protein interactions and a significantly
transcriptionally affected subnetwork, HSN, was identified. (3) Each gene set was tested for overrepresentation in each HSN based on a Fisher’s exact
test. A gene set was considered enriched in the condition if the Fisher’s p-value fell below 0.05. (4) Gene sets were ordered based on the number of
conditions in which they were enriched. (5) For each gene set, the number of conditions in which it was enriched was assigned a p-value based on
comparison against a background distribution.
doi:10.1371/journal.pgen.0030096.g001
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microarrays generated by 16 projects for DGAP (see Text S1
for details). Detailed descriptions of each particular experi-
ment along with the expression data can be found on the
DGAP website [12]. These experiments had different designs
with respect to organism (human or mouse), tissue type
(adipose, liver, muscle, and pancreas), and models of insulin
resistance and diabetes.
The data were grouped into 67 different gene-expression
profiles, collectively designated as DGAP conditions, follow-
ing the designs and setups of the original experiments. A total
of 65 of these 67 conditions directly compared between an
insulin resistant or diabetic phenotype to a control pheno-
type within an experiment. The remaining two conditions
compared between insulin-dependent response phenotypes
under fasting and fed states within an experiment (see
Datasets S1, S2, and S3 for details). The expression profiles of
all the genes in the 67 conditions were designated as the
DGAP expression data.
The global protein–protein interaction network was
obtained from the HPRD. For each of the DGAP conditions,
the p-value (significance of expression change between insulin
resistant or diabetic and control state) of every gene was
mapped onto the corresponding protein in the network. This
generated a set of condition-specific, protein–protein inter-
action networks wherein each protein is labeled with a p-
value for each condition (see Text S3 for details). In other
words, while the network interactions were static, the p-values
associated with the genes and proteins changed per con-
dition. It is important to note that genes with no correspond-
ing proteins in the protein–protein interaction network were
not included in the analysis. Similarly, proteins in the HPRD
without a corresponding gene in the DGAP expression data
were excluded from the protein–protein interaction network
along with all associated interactions.
For each gene set, annotation of the corresponding
proteins in the condition-specific, protein–protein interac-
tion network produced a functional subnetwork.
High-Scoring Networks: Putative Noisy Molecular Models
of Disease
A network search algorithm was used to identify an HSN
per condition-specific protein–protein interaction network.
The algorithm attempted to identify an interaction subnet-
work whose cumulative expression level (based on an average
of the expression for the individual nodes) was differentiated
from the background. It is important to note that the
subnetwork allowed the inclusion of genes that were not
found as individually significant but that were connected to
other significant genes through protein–protein interactions.
This feature allowed genes with known interactions to other
transcriptionally active genes to be included, even if they did
not exhibit high transcriptional activity themselves. There-
fore, such a subnetwork containing a large number of
transcriptionally affected members and associated protein–
protein interactions could be considered a putative noisy
molecular model of the disease condition.
We used the Cytoscape plug-in, ActiveModules, to find an
HSN for each condition. The plug-in employed a published
algorithm [21], which consisted of a network scoring metric
and a network search function. For a given network, the
network score was computed as a standardized weighted
average of the z-scores for the individual network nodes. The
network search function was a simulated annealing algorithm
that accounted for the effects of highly connected nodes
(hubs) on the network score. Given the stated scoring metric
and search function, the algorithm would find a subnetwork
with a high score relative to its size. Because the network
score was a weighted average of the z-scores of the individual
member nodes, a network with a high score would be one
where many of the individual members have relatively low p-
values; i.e., the network, as a whole, would be differentially
expressed in the disease condition (see Text S4 for additional
details).
Determining Gene-Set Enrichment in a Condition
To determine if a gene set, or equivalently, its functional
subnetwork, was transcriptionally affected in a given con-
dition, we tested if members of the gene set appeared
disproportionately in the HSN for that condition, relative to
the global network of protein–protein interactions. This was
accomplished using Fisher’s exact test, with a confidence level
a¼0.05, and the gene set was considered enriched in the HSN
if the p-value fell below a.
Ranking Gene Sets by Number of Enriched Conditions
To identify the gene sets that were consistently deregulated
across many DGAP conditions, each gene set was evaluated to
see if its members were disproportionately present in many
HSNs. The score of a gene set was defined as the number of
HSNs in which it appeared enriched. Higher scores equated
with enrichment of the gene set in more conditions, and the
gene sets in the collection could be sorted and ranked based
on their respective scores.
Assigning Significance to Gene-Set Scores
A random walk approach on the protein–protein inter-
action network was used to determine the significance of a
gene set’s score. Specifically, 10,000 gene sets of the same size
as the given set were generated by a random walk of the
protein–protein interaction network (see Text S5 for details).
Each random gene set was scored according to the method
outlined above, and a distribution of all 10,000 scores was
subsequently generated. The percentage of the random gene
sets with scores equal to, or higher than, the given set was
taken as the empirical p-value of the given set’s score. p-
Values ,0.05 were considered significant. By comparing the
gene set against random gene sets of the same size, the
potential effects of the gene set’s size on its score would be
taken into account when determining the p-value.
Because HSNs were connected subnetworks, gene sets that
formed dense functional subnetworks could potentially be
identified as enriched in multiple HSNs by random chance.
To determine potential biases towards dense networks and
improve confidence in the identified gene sets, an additional
analysis was performed on gene sets with significant p-values.
For each significant gene set, the densities for 10,000
random gene sets were determined in addition to their
scores. Under the premise that dense networks were biased
towards higher scores, the expectation would be to see a
nondecreasing relationship between network densities and
gene-set scores. A plot of network density versus gene-set
score should then show such a relationship. If no such
relationship was evident, then high network density could not
have had a strong positive effect on the enrichment result.
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Software Availability
A documented distribution of the source code for the
GNEA algorithm described in this paper is available from the
authors upon request.
Results
Impairment or alteration of the insulin-signaling pathway
is a commonly recognized feature of type 2 diabetes. It is
therefore notable that the IS-HD gene set (Dataset S4) was
not detected to be significantly transcriptionally altered by
application of either hypergeometric enrichmentt test, DEA
or GSEA. In particular, applying GSEA to the transcriptional
profile dataset of diabetic and normal glucose-tolerant
skeletal muscle described in Mootha et al. [10] did not
identify a significant level of alteration in the IS-HD gene set
(p ¼ 0.536), while DEA produced a comparably weak enrich-
ment score (p ¼ 0.607). The failure to detect a significant
transcriptional alteration in IS-HD may be explained by a
number of factors. The enrichment results depended on the
specific choice of the IS-HD gene set, and it is possible that an
alternatively defined insulin-signaling gene set would be
determined as significantly enriched. Additionally, expression
changes in a few critical genes in IS-HD may be sufficient to
substantially alter insulin signaling, and running DEA on the
large IS-HD set may miss the contributions from these few
genes.
Interestingly, running GNEA on the dataset identified a
significant alteration in the transcriptional profile of IS-HD.
Because this particular analysis involved only a single dataset,
the GNEA framework might not be strictly applicable and IS-
HD was only assessed for overrepresentation in the HSN by
Fisher’s exact test and found to have a p-value of 0.034. To
determine the robustness of the identified signature, 100
additional DM2 datasets were generated from the original
using a bootstrap resampling technique [22]. Namely, each of
the new datasets was generated by random sampling, with
replacement, of individuals in the original. The mean p-value
of the Fisher’s exact test on the new datasets was 0.033 and
the standard deviation was 0.092. To further improve our
confidence in the result, a separate, nonrandom dataset was
analyzed that compared between type 2 diabetic and normal
individuals with no family history of type 2 diabetes [11]. IS-
HD was also identified as transcriptionally altered in that
dataset with a p-value of 0.026.
In addition, two lung cancer datasets [23,24] were also
selected and analyzed using GNEA. A priori, identification of
IS-HD in the two datasets would have reduced confidence in
the relevance of the signature to DM2. IS-HD was, in fact, not
identified in either of the two datasets, lending support to its
possible relevance to the DM2 disorder.
The recurring signature of IS-HD alteration using boot-
strap from a DM2 dataset and multiple insulin-resistance
models in mouse improves our confidence in its relevance.
The encouraging results motivated the larger study using
model organisms described below and obviously require
additional validation on a larger population of diabetic
patients. It is also important to note that the positive GNEA
result does not detract from the significance of DEA, GSEA,
and related methods in other detection tasks (see results on
glucose and fatty acid metabolism GO categories below).
The graphical result of the GNEA analysis on the skeletal
muscle dataset is illustrated in Figure 2. As suggested
intuitively by the figure and associated Fisher’s exact test
enrichment result (p ¼ 0.034), the set of protein–protein
interactions associated with the insulin-signaling pathway was
significantly affected in diabetic skeletal muscle tissue
compared to normal muscle tissue.
Motivated by the preliminary analysis of diabetic muscle
tissue, we applied the GNEA methodology to the microarray
gene-expression datasets compiled by the DGAP project.
Insulin signaling, as represented by IS-HD, was found
significantly transcriptionally altered in the largest number
of insulin resistance and diabetes conditions compared to any
other tested gene sets. The results confirm that insulin
signaling is a strongly affected biological process in insulin
resistance and diabetes. IS-HD was significantly affected
across adipose, skeletal muscle, liver, and pancreatic tissue.
While it may seem like a foregone conclusion to find changes
in insulin signaling in insulin resistant conditions, the fact is
that IS-HD was not identified as enriched in a significant
number of conditions by DEA. Specifically, DEA found
transcriptional alteration in IS-HD in only one condition
comparing mouse liver tissue in high and low-fat diets.
Insulin signaling is assumed to be deregulated in diabetes and
insulin resistance phenotypes. The failure of DEA to find such
deregulation in comparison to the success of GNEA under-
scores the importance of integration with network models
(even in the form of protein–protein interactions) to enhance
the ability to detect a biological signal.
NR-HD was the second prominent gene set identified as
significantly and consistently altered in diverse insulin-
resistance models. Both IS-HD and NR-HD showed a wide-
spread interactive role across different disease states (Figure
3), an abundance that was unmatched by any of the other
tested gene sets (Figure 4). Furthermore, as suggested in
Figures S2 and S3, the density of the gene sets in the
underlying protein–protein interaction network did not
appear to have had a strong effect on the scores for IS-HD
and NR-HD.
Figure 4 summarizes the GNEA results for all tested gene
sets and clearly demonstrates the distribution of the number
of gene sets enriched in a given number of insulin resistance
and diabetes conditions. The IS-HD and NR-HD sets were
distinctly enriched in many more conditions than any other
tested gene sets. The high enrichment of IS-HD may be
explained by the central role of insulin signaling in insulin
resistance phenotypes and the fact that many DGAP experi-
ments specifically disrupted critical components of insulin
signaling. The result for NR-HD requires further explanation.
Individual nuclear receptors, such as HNF4A and PPARGs
have been implicated in insulin resistance and type 2 diabetes
in the past [13–17]. More generally, many nuclear receptors
are known to form monomeric, heterodimeric, or homodi-
meric complexes and act to regulate diverse metabolic
processes [25]. Because the NR-HD set was dominated by
nuclear receptors and their cofactors, it is possible that the
high enrichment of the set was a consequence of the key
metabolic roles played by individual nuclear receptors,
coupled with their interactions with cofactors and other
partners. Under this scenario, the NR-HD set may be viewed
as a compilation of key players involved in the metabolic
distress phenotypes associated with DM2.
Intriguingly, when the genes in NR-HD were ranked by the
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number of times they appeared in all the HSNs, no individual
gene appeared more than 18 times. Given that the NR-HD set
was enriched in 31 conditions, this suggested that different
subsets of NR-HD were responsible for the enrichment in
different conditions. To investigate whether a recurring
subnetwork of NR-HD was responsible for enrichment in
multiple conditions, we computed a Pearson correlation
coefficient for every pair of genes in NR-HD based on their
binary profile of appearances in the 31 enriched HSNs. While
some genes tended to cluster, no group of genes stood out as
strongly correlated in these profiles (Figure S4). The results
suggested that different insulin resistance conditions were
associated with deregulation of different subsets of NR-HD.
This scenario illustrates an advantage of the GNEA approach
over more conventional ones such as DEA. While the latter
may identify enrichment of individual NR-HD members, it
would fail to find enrichment of the set as a whole since no
gene appeared enriched in as many conditions as the total set.
The NR-HD set was also identified as significantly tran-
scriptionally altered by DEA. However, DEA identified NR-
HD enriched in far fewer conditions than GNEA (six
compared to 31). Interestingly, the three other nuclear
receptor gene sets were not identified as enriched in a
significant number of conditions by either DEA or GNEA.
The lack of enrichment in the nuclear receptor superfamily
gene set can be explained by the different patterns of
expression of individual nuclear receptors in diverse tissues
[26]. However, the similar results for the HUGO nuclear
receptor gene set, and the union of these two gene sets,
supported a broader conclusion. Since none of the three
nuclear receptor gene sets were enriched in a significant
number of conditions while NR-HD was, the results suggested
that only a specific subset of nuclear receptors (including the
Figure 2. Comparison of Type 2 Diabetic and Normal Glucose Tolerant Skeletal Muscle
(Left) The HSN is shown. Interactions involving at least one IS-HD member are highlighted in red. Those involving at least one NR-HD member are
highlighted in green. Of the 417 nodes in the HSN, 102 belonged to or interacted directly with IS-HD or NR-HD members.
(Right) The 102 nodes in the HSN formed a network signature. GNEA identified IS-HD, but not NR-HD, as enriched in this dataset. IS-HD and NR-HD
members are highlighted in red and green, respectively.
doi:10.1371/journal.pgen.0030096.g002
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NR-HD genes) and their constellated cofactors was differ-
entially associated with insulin resistance and DM2.
NR-HD Was Enriched in Many DGAP Conditions
The NR-HD set (Figure 5) was found enriched in 31
conditions by GNEA (raw p¼0.0030 and false discovery rate¼
0.0179) and in six by DEA (p ¼ 0.0125, false discovery rate ¼
0.0875). The two methods found six conditions in common
where NR-HD was enriched. All of the found conditions from
GNEA or DEA corresponded to comparisons between an
insulin resistant or diabetic state and normal. The 31
conditions spanned 13 adipose, nine liver, and nine skeletal
muscle tissues. The six conditions spanned three adipose, two
liver, and one skeletal muscle tissue. Some genes in NR-HD
had well-documented associations with DM2, such as PPARG,
PPARGC1A, and HNF4A [10,13–17]. Other genes from the NR-
HD set could also be connected to DM2 via their associations
with diabetes risk factors, including glucocorticoid receptor (GR,
also known as NR3C1) [27] and vitamin D receptor (VDR) [28].
While these genes had been individually associated with
Figure 3. IS-HD and NR-HD Signaling
(A) Protein–protein interactions appearing in at least one HSN are assembled together to form the network signature shown. Interactions involving at
least one IS-HD member are in red. Those involving at least one NR-HD member are in green. (Interactions between IS-HD and NR-HD members are
shown in green).
(B) A subgraph of the same network that includes only the top 5% most frequently appearing genes in the HSNs is shown. Both IS-HD and NR-HD
members clearly participate in numerous protein–protein interactions.
doi:10.1371/journal.pgen.0030096.g003
Figure 4. Frequency Histogram of Gene-Set Scores by GNEA
This analysis used 353 gene sets, consisting of 346 GO categories, two retinol metabolism-signaling sets, three nuclear receptor sets, and the IS-HD and
NR-HD gene sets. The indicated positions for the IS-HD (45) and NR-HD (31) gene sets correspond to the number of conditions where they were
identified as enriched.
doi:10.1371/journal.pgen.0030096.g004
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insulin resistance and DM2 in the past, to our knowledge, this
was the first time a set of nuclear receptors had been
identified as significantly transcriptionally altered in multiple
insulin resistance and diabetes models. The set also included
genes related to retinol metabolism and signaling, such as
retinoic-acid receptor alpha (RARA), retinoid X receptor alpha
(RXRA), and retinoic-acid receptor-related orphan receptor alpha
(RORA). Previous studies had suggested a possible connection
between retinol metabolism signaling and DM2 [29–31]. As
illustrated in Figure 5, 13 NR-HD genes were nuclear
receptors, some of which acted as mediators for diverse
metabolic processes [25,32]. The remaining 17 NR-HD genes
were nuclear receptor coregulators. The distribution of gene
memberships in the 31 HSNs found enriched by GNEA was
examined and grouped by tissue type, with the results shown
in Figure 6. v-raf-1 murine leukemia viral oncogene homolog 1
(RAF1) was present in the most number of HSNs, appearing
in 13 of the 31 conditions and all three tissue types. GR was
the most frequently appearing nuclear receptor, present in
nine of the conditions and also all three tissue types. Certain
genes tended towards specific tissue types: four and a half LIM
domains 2 (FHL2) appeared in eight conditions overall, five of
which were skeletal muscle. Nuclear receptor subfamily 2, group F,
member 1 (NR2F1) appeared in six conditions overall, four of
which were adipose.
IS-HD Was Enriched in Many DGAP Conditions
The IS-HD set was found enriched in 45 conditions by
GNEA (raw p ¼ 0.0050, false discovery rate ¼ 0.0179) that
compared between an insulin resistant or diabetic state and
normal. The conditions spanned diverse tissues (13 adipose,
13 liver, 18 skeletal muscle, and one pancreas tissue) and
suggested a widespread tissue independent effect. When the
genes in IS-HD were ranked by the number of times they
appeared in the 67 HSNs, no individual gene appeared more
than 18 times. This result suggested that, similar to NR-HD,
different components of IS-HD were being deregulated in
different insulin resistance models. This is consistent with the
fact that multiple deregulatory models exist for insulin
resistance [33,34]. Figure 7 summarizes the results for NR-
HD and IS-HD under both GNEA and DEA.
Overlap between NR-HD and IS-HD
GNEA identified IS-HD significantly enriched in 45
conditions and NR-HD in 31. Both were identified enriched
in 22 conditions spanning nine adipose, seven liver, and six
skeletal muscle tissue. One explanation for the overlap is that
certain genes may act as signaling mediators or serve dual
functions between the two gene sets. Transcriptional alter-
ation in one set may therefore affect the other. To pursue this
hypothesis, protein–protein interactions between IS-HD and
NR-HD were identified and examined. The interactions were
observed to form a connected subnetwork (Figure 8). IS-HD
genes involved in these interactions included the signal
transducer and activator of transcription family (STAT5A, STAT5B,
and STAT1), janus kinases (JAK1 and JAK2), and tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation proteins,
(YWHAB, YWHAZ, and YWHAE). NR-HD genes included
androgen receptor (AR), breast cancer 1 (BRCA1), and GR (also
known as NR3C1) among others. Interestingly, RAF1, which
participated in the most interactions between the two gene
sets, was also a member of both. Possibly, among other
potential signal transductions, insulin deregulation may
propagate a signal through RAF1 to the nuclear receptors.
GNEA and DEA: Side-by-Side Comparison
As previously mentioned, GNEA found IS-HD and NR-HD
enriched in 45 and 31 conditions, respectively, whereas DEA
found enrichment in only one and six. In addition, we
systematically compared the results from GNEA and DEA on
the two retinol signaling gene sets and three nuclear receptor
gene sets, as well as the group of 346 GO category gene sets
present in the DGAP expression data. None of the retinol
signaling or nuclear receptor gene sets appeared enriched in
a significant number of conditions by either method. Top-
scoring GO categories in GNEA included RNA splicing, cell-
growth/death regulation, and nuclear receptor signaling
processes with the latter category explained by the strong
enrichment of the NR-HD set. Top ranked GO categories in
DEA include metabolism and cell-growth/death-regulation
processes. Growth is intimately tied to metabolism, and the
appearance of such categories in both GNEA and DEA may
be explained by the deregulation of the latter. Moreover,
certain nuclear receptors had been associated with apoptosis
pathways and cancer in the past [35,36], and the top scores of
cell-growth/death-regulation GO categories were likely partly
due to the general enrichment of the NR-HD set members.
Excluding IS-HD and NR-HD, no tested, potentially
Figure 5. The NR-HD Gene Set
The NR-HD gene set was composed of 13 nuclear receptors (green) and
17 nuclear receptor coregulators (gold). Black edges denote interactions
documented in the most recent HPRD version that were not well
documented in the version used in the analysis.
doi:10.1371/journal.pgen.0030096.g005
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disease-associated gene set scored significantly by GNEA, nor
did any GO category gene sets. Interestingly, a number of
metabolism-related GO categories scored significantly by
DEA. Because insulin resistance is associated with dysregula-
tion of metabolism, the expectation was to see a significant
score for such GO categories. DEA results confirmed the
expectation whereas GNEA did not. In particular, GO
categories such as GO:0006006 (glucose metabolism) and
GO:0006631 (fatty acid metabolism) had very low scores in
GNEA and demonstrated a caveat with the network-based
approach. The low gene-set scores resulted from the very
disconnected functional subnetworks for these gene sets.
Because HSNs were connected subnetworks, gene sets with
connected functional subnetworks tended to be better
represented in an HSN than those without. By implication,
biological processes that were poorly represented by protein
interactions, such as oxidative phosphorylation, would be
missed by GNEA. While an acknowledged shortcoming, we
note that disconnected gene sets in the present will become
increasingly connected in the future as knowledge about
them accumulates with time and as the interactions of
member genes are cataloged by the on-going efforts of
projects such as the HPRD [37]. At present, the GNEA
methodology provably succeeded at identifying two gene sets,
NR-HD and IS-HD, which were clearly associated with insulin
resistance models despite this caveat. Hence, its utility is clear
even with the presently available information.
Little Expression Correlation among Insulin Resistance
Models
We computed a Pearson correlation coefficient between
every pair of DGAP conditions based on their global gene
expression (Figure 9). The results suggested reasonably little
gene-expression correlation between different insulin resist-
ant models. The lack of clustering reinforced the observation
that different sets of genes and cause-effect mechanisms were
responsible for the insulin resistance phenotype in different
models.
Discussion
In its most ambitious form, system biology aims to
understand the molecular mechanisms of normal and disease
states and develop a better understanding of genetic and
environmental factors, including drugs, affecting these
mechanisms in different conditions. System level approaches
have been generating increasingly deeper insights in areas
where the combination of current knowledge and measure-
ment technologies provide a sufficiently accurate and
interpretable snapshot of biological processes [38–41]. In
particular, integration of genome-wide measurements and
protein–protein interaction networks has produced a num-
ber of functional and regulatory predictions that have been
validated in biological assays. We follow this integrative
approach by introducing GNEA, a simple but promising
strategy for identifying transcriptionally altered processes in
Figure 6. The Distribution of NR-HD Gene Memberships in the 31 HSNs
The height of the bars reflects the number of HSNs in which a NR-HD gene appeared. NR-HD was enriched in 13, nine, and nine conditions associated
with adipose, liver, and skeletal muscle, respectively.
doi:10.1371/journal.pgen.0030096.g006
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a set of abnormal biological states caused by disease or
pharmacological interventions. GNEA differs from tradi-
tional enrichment approaches in a number of ways. First, it
makes use of protein–protein interaction information.
Second, it examines transcriptionally altered sets of genes
rather than individual genes. Finally, it integrates gene-
expression datasets from diverse disease models. Each of
these distinctions confers an advantage to GNEA over widely
used methods such as DEA as well as some potential caveats.
By organizing genes into a network based on the physical
interactions among their protein products, GNEA imposes
constraints on the relationships between genes. It has
previously been demonstrated that, with the exception of
protein complexes, genes with interacting protein products
do not necessarily have well-correlated gene-expression
profiles [42]. Protein–protein interactions therefore repre-
sent a nonredundant line of evidence that can be combined
with gene-expression information to elucidate the interrela-
tionships between genes and their participation in biological
processes. For biological processes with well-characterized
protein interactions, such as insulin signaling, GNEA demon-
strably identifies those that are altered in disease phenotypes.
However, it is less effective in situations where the biological
processes are poorly characterized in terms of protein–
protein interactions or where such information is potentially
inaccurate. In the former, GNEA may fail to find enrichment
of a gene set because the interaction information is
insufficiently comprehensive and the gene-set members are
highly disconnected from one another as a result. In the
latter, GNEA may give an inaccurate result because the
protein–protein interaction information itself contains in-
accuracies. Considering its dependence on reliable protein–
protein interaction information, GNEA is best viewed as a
complement to existing methods, such as DEA and GSEA [18],
which do not rely on such information. For situations where
the protein–protein interaction information is comprehen-
sive, the results from GNEA are likely more sensitive. When
protein–protein interaction information is lacking, such
results may be considered subordinate to those from the
other methods.
GNEA tests for transcriptional alteration in sets of genes
rather than individual genes. Under this approach, individual
genes are not required to be differentially expressed in order
to identify biological processes or gene sets that are
cumulatively differentially expressed. Some genes, such as
transcription factors, play important roles in biological
processes without necessarily showing a large change in
transcriptional activity when the processes are altered. Gene
sets that contain many such genes would be missed under the
criterion that individual genes be differentially expressed.
GNEA provides an alternative where a gene’s expression
value and its interactions with other genes are both taken
into consideration. In this way, genes that are not individually
significant may still be taken into account if they are
connected to other significant genes. As examples, both IS-
HD and NR-HD contained individually nonsignificant genes
Figure 7. GNEA and DEA Enrichment Results for Both NR-HD and IS-HD
NR-HD was enriched in 31 and six conditions by GNEA and DEA, respectively, and IS-HD was enriched in 45 and one. The distribution of enrichments in
adipose, liver, and skeletal muscle tissue is shown. IS-HD was additionally enriched in one DGAP condition in pancreatic tissue by GNEA (not shown).
doi:10.1371/journal.pgen.0030096.g007
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despite being identified as cumulatively differentially ex-
pressed sets (Dataset S5). In the converse situation, a dataset
may contain thousands of differentially expressed genes, in
which case numerous gene sets would be overrepresented in
differentially expressed genes. GNEA also applies in this
instance by favoring those gene sets with well-connected
members in the protein–protein interaction network. The
downside to such an approach is that, in common with all
gene-set enrichment approaches, the enrichment result for
any gene set will depend on its composition. For a given
biological process, two different, yet equally representative,
sets of genes may happen to show different enrichment
results. We emphasize, however, that while the composition of
the gene sets may affect the enrichment results, the sizes of
the gene sets do not. As previously described in the Methods
section, GNEA explicitly compares the performance of each
test gene set against those from random gene sets of the same
size. Biases resulting from the sizes of the test gene sets are
therefore taken into account when determining the signifi-
cance values.
The third distinction between GNEA and existing methods
is its focus on identifying biological signals that are recurrent
across multiple, rather than individual, conditions. While
such a focus allows GNEA to pick up biological signals that
might otherwise be missed in any one condition individually,
it also means that the analysis is influenced by the choice and
number of conditions being tested. Some biological processes
of interest may be enriched in only a specific subset of the
total conditions being tested. Such processes may be missed
when the total number of tested conditions is large. The
signal is effectively diluted because the conditions are too
removed from the context where the process is active.
Selecting the proper and relevant conditions for testing must
therefore be done carefully. The converse situation is also
possible. When the number of tested conditions is low, even a
gene set that is enriched in all conditions may nonetheless
have an insignificant p-value, as the probability of such an
observation occurring by random chance is high. In such
instances, one potential workaround is to employ a bootstrap
approach similar to the one described for the validation of
the IS-HD enrichment signal in the DM2 dataset (see Results).
Finally, it should be noted that the effect of constraining
genes by protein–protein interactions and then testing for
gene-set enrichment by GNEA is different from the effect of
Figure 8. Protein–Protein Interactions between NR-HD and IS-HD
The protein–protein interactions between members of NR-HD (in green) and IS-HD (in red) in the conditions where both sets appear enriched form a
mostly connected network. RAF1 (in blue) was a member of both sets. Of the 33 total interactions, 16 involved RAF1. Interactions shown in dotted
black, solid black, dotted blue, and solid blue appeared in one, two, three, and four HSNs, respectively.
doi:10.1371/journal.pgen.0030096.g008
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merely lowering the significance threshold and testing for
gene-set enrichment by DEA. In general, not all genes in a
dataset are connected to each other through protein–protein
interactions. Consequently, the genes taken into consider-
ation by GNEA would be different from the ones determined
by significant value alone, independent of the significance
level used. Because the connection between genes by protein
interactions is independent of the significance level, GNEA is
potentially less dependent on the threshold used to identify
differentially expressed genes compared to conventional
methods such as DEA [43].
Our work shares the philosophy advocated in He and
Zhang [44]. There, the authors argued that the reason many
hubs in protein–protein interaction networks correspond to
essential proteins is that hubs have a higher probability of
involvement in essential protein–protein interactions. This
paradigm, of identifying variables correlating with key
protein–protein interactions, might be generalized to phe-
notypes such as insulin resistance. That is, the identification
of processes with relatively many protein–protein interac-
tions essential for proper insulin sensitivity might assist the
identification of those affected in insulin resistance.
GNEA is not the first method to integrate gene-expression
data with protein–protein interaction information for
various analytical tasks. For example, Steffen et al. [45] and
Ideker et al. [46] combined gene-expression data with
protein–protein interaction networks to identify signal
transduction pathways in yeast. Others, such as Karaoz et al.
[47], attempted to improve functional gene classification. In
contrast, GNEA aims to detect biological processes that are
consistently altered across multiple disease models. Gene-
expression measurements are integrated with protein–pro-
tein interaction information to identify transcriptionally
affected subnetworks that can be considered as noisy
molecular signatures of specific disease conditions. Biological
processes that are overrepresented in a significant number of
disease models are identified as deregulated in the pheno-
type.
Using GNEA, our results indicated that the insulin-signal-
ing process is significantly transcriptionally altered in insulin
resistance and DM2. While this observation appears quite
natural, it remains that other techniques have difficulty
detecting such a deregulation. The alteration in insulin
signaling was identified across adipose, liver, skeletal muscle,
Figure 9. Pearson Correlation Coefficients between Every Pair of DGAP Conditions
The gene-expression profiles for the DGAP conditions, (indexed by their numerical identifiers, Dataset S3), were generally poorly correlated.
doi:10.1371/journal.pgen.0030096.g009
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and pancreas tissues. Insulin signaling is well associated with
DM2, and the relationship between impairment in this
biological process and insulin resistance has been supported
by numerous clinical investigations and genetic studies. The
results likewise implicated a specific set, NR-HD, of nuclear
receptors whose individual members are known to be
involved in diverse sensory and transcriptional processes
and have been previously associated with insulin resistance
and DM2. The nuclear receptor set includes HNF4A, PPARG,
PPARGC1A, and other genes that have been implicated with
diabetes in previous association and linkage studies
[10,27,48–50]. The association of NR-HD with changes in
transcriptional activation is somewhat surprising as nuclear
receptors are ligand activated. Further studies will be needed
to examine the roles played by the NR-HD genes, their
relationships to each other, and the nature of their
association, as a set, with DM2 and insulin resistance models.
IS-HD and NR-HD members were shown to interact in a
mostly connected, protein–protein interaction network.
Moreover, RAF1 was demonstrated to be a hub in many of
these interactions, across a variety of tissue types, and may be
an important signaling mediator between the two processes.
In addition to RAF1, other NR-HD genes were also observed
to be protein–protein interaction hubs.
More generally, the results for the insulin signaling and
nuclear receptor sets suggest that different members of these
sets were transcriptionally altered under different insulin-
resistance models. Different insulin-resistance models also
showed little correlation in gene expression with each other.
While these results might be a consequence of biological or
experimental noise common to microarray studies, they are
also consistent with the notion of a combinatorial disease
model whereby deregulation of different and small sets of
genes may independently lead to the insulin resistance
phenotype.
Supporting Information
Dataset S1. Experimental Description for Each of the 16 DGAP
Datasets
This table gives a brief description of each of the DGAP datasets used
in the analysis. Full experimental details are available on the DGAP
website (http://www.diabetesgenome.org). The first column lists the
dataset identifier (16 total, identifiers ‘‘3’’ and ‘‘9’’ are absent). The
second column iterates the Affymetrix microarrays used in each
dataset. The third and final column gives a brief description of the
experimental design in each dataset.
Found at doi:10.1371/journal.pgen.0030096.sd001 (15 KB XLS).
Dataset S2. Information on Each of the 361 Microarrays
This table gives a brief description of each of the microarrays used in
the analysis. Full experimental details are available on the DGAP
website. The first column lists the dataset (indexed by dataset
identifier) from which the model was taken. The second and third
columns iterate the Affymetrix microarray type and number of them
used to profile the model. The fourth through seventh columns give a
short description, species, sampled tissue type, and expected
genotype of the model, respectively. The final column gives a fuller
description of the model.
Found at doi:10.1371/journal.pgen.0030096.sd002 (48 KB XLS).
Dataset S3. Information on Each of the 67 Conditions
This table details the comparison between the perturbed state and
normal for each of the DGAP conditions. The first column gives the
condition identifier for each model. Models with the same condition
identifiers are compared to each other in the specified condition. It is
important to note that the condition identifiers run from 1 to 54, and
then from 56 to 68. Condition number 55 was not analyzed because
the models being compared in it contained mislabeled data. The
second and third columns list a short description and sampled tissue
type of each of the models being compared.
Found at doi:10.1371/journal.pgen.0030096.sd003 (26 KB XLS).
Dataset S4. The IS-HD Gene Set and Protein–Protein Interactions
This table includes all members in the IS-HD gene set and lists all
edges in the IS-HD functional subnetwork. Gene members are
referenced by their National Center for Biotechnology (http://www.
ncbi.nlm.nih.gov) gene symbol. The genes in the first column share an
edge with those in the second. Genes without a partner in the second
column are disconnected in the functional subnetwork.
Found at doi:10.1371/journal.pgen.0030096.sd004 (17 KB XLS).
Dataset S5. IS-HD and NR-HD Gene Significance Values in the 67
Conditions
This table contains the significance values of all genes in IS-HD and
NR-HD for each of the DGAP conditions, prior to multiple-testing
correction. The first four columns list the human gene symbols,
Entrez Gene databank identification numbers, membership in IS-HD,
and membership in NR-HD. The remaining 67 columns, indexed by
condition identifiers, give the significance values of the genes in each
condition.
Found at doi:10.1371/journal.pgen.0030096.sd005 (165 KB XLS).
Figure S1. Overview of DEA
(1) A collection of gene sets associated with biological processes was
assembled. (2) Each gene set was tested for overrepresentation in
differentially expressed genes (p , 0.05) based on a Fisher’s exact test.
A gene set was considered enriched in the condition if the Fisher’s p-
value fell below 0.05. (3) We repeat step 2 for each condition. (4) Gene
sets were ordered based on the number of conditions in which they
are enriched. (5) For each gene set, the number of conditions in
which it is enriched was assigned a p-value based on comparison
against a background distribution.
Found at doi:10.1371/journal.pgen.0030096.sg001 (465 KB PDF).
Figure S2. Scatter-Plot of Network Density versus Gene-set Score for
NR-HD
The network densities for 10,000 random gene sets of the same size as
NR-HD were plotted versus their gene-set scores. Network density did
not appear to have had a strong, positive effect on gene-set score.
Found at doi:10.1371/journal.pgen.0030096.sg002 (894 KB PDF).
Figure S3. Scatter-Plot of Network Density versus Gene-Set Score for
IS-HD
The network densities for 10,000 random gene sets of the same size as
IS-HD were plotted versus their gene-set scores. Network density did
not appear to have had a strong positive effect on gene-set score.
Found at doi:10.1371/journal.pgen.0030096.sg003 (946 KB PDF).
Figure S4. Pearson Correlation Coefficients between NR-HD Genes
Each NR-HD gene was associated with a binary profile of appearances
in the 31 HSNs where NR-HD was enriched. The Pearson correlation
coefficient was computed for every pair of genes in NR-HD based on
their binary profiles. No group of genes stood out as strongly
correlated in these profiles.
Found at doi:10.1371/journal.pgen.0030096.sg004 (311 KB PDF).
Text S1. Compilation of the Gene-Expression Data
Found at doi:10.1371/journal.pgen.0030096.sd006 (25 KB DOC).
Text S2. Assembly of the Gene Sets
Found at doi:10.1371/journal.pgen.0030096.sd007 (35 KB DOC).
Text S3. Assembly of the General and Condition-Specific Interaction
Networks
Found at doi:10.1371/journal.pgen.0030096.sd008 (24 KB DOC).
Text S4. Cytoscape Algorithm and Running Parameters
Found at doi:10.1371/journal.pgen.0030096.sd009 (20 KB DOC).
Text S5. Procedure to Generate Random Gene Sets in GNEA and
DEA
Found at doi:10.1371/journal.pgen.0030096.sd010 (20 KB DOC).
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Accession Numbers
The Entrez Gene databank (http://www.ncbi.nlm.nih.gov/entrez) ac-
cession numbers for the genes discussed in this paper are AR, 367;
BRCA1, 672. ; FHL2, 2274; GR, 2908; HNF4A, 3172; JAK1, 3716; JAK2,
3717; NR2F1, 7025; PGC1A, 10891; PPARG, 5468; RAF1, 5894; RARA,
5914; RORA, 6095; RXRA, 6256; STAT1, 6772; STAT5A, 6776; STAT5B,
6777; VDR, 7421; YWHAB, 7529; YWHAE, 7531; and YWHAZ, 7534.
Entrez Gene databank accession numbers for all additional genes
in the IS-HD and NR-HD gene sets can be found in Dataset S5.
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